China Pharma Holdings, Inc.
CPHI · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5 | $7 | $8 | $10 |
| % Growth | -35.4% | -13.5% | -15.9% | – |
| Cost of Goods Sold | $7 | $7 | $9 | $9 |
| Gross Profit | -$2 | -$0 | -$0 | $0 |
| % Margin | -43.8% | -4% | -6.1% | 3.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $1 | $2 | $2 |
| SG&A Expenses | $2 | $2 | $3 | $3 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | -$0 | -$0 | -$0 |
| Operating Expenses | $3 | $2 | $3 | $3 |
| Operating Income | -$5 | -$3 | -$4 | -$3 |
| % Margin | -101.3% | -39.2% | -43.8% | -29.7% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$1 |
| Pre-Tax Income | -$5 | -$3 | -$4 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$3 | -$4 | -$3 |
| % Margin | -104.6% | -43.9% | -49% | -35.3% |
| EPS | -0.27 | -0.29 | -1.94 | -0.85 |
| % Growth | 6.9% | 85.1% | -128.2% | – |
| EPS Diluted | -0.27 | -0.29 | -1.94 | -0.85 |
| Weighted Avg Shares Out | 17 | 11 | 5 | 5 |
| Weighted Avg Shares Out Dil | 17 | 11 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $3 | $3 | $3 | $3 |
| EBITDA | -$2 | $0 | -$1 | $0 |
| % Margin | -43.4% | 0.1% | -10.3% | 2.4% |